Shukra Pharmaceuticals profitability ratios

Per cent unless marked ×
Tap a line for its trendFY24Mar 2024FY23Mar 2023
Returns
44.7%17.4%
24.3%5.9%
32.2%13.2%
Margins
26.0%9.1%
23.3%6.0%
87.9%—
26.7%7.5%
24.9%7.5%
−9.3%−2.3%
Additional
6.8%0.8%
0.4%1.7%
44.5%17.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SHUKRAPHAR₹75.06

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOCMcap ₹60.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Returns
Return on Common Equity17.4244.70
Return on Assets5.8824.26
Return on Invested Capital13.2532.15
Margins
EBITDA Margin9.1226.02
Operating Margin5.9923.27
Incremental Operating Margin—87.85
Pretax Margin7.5526.66
Net Income Margin7.4924.86
FCF Margin-2.25-9.33
Additional
Effective Tax Rate0.796.77
Dvd Payout Ratio1.650.38
Sustainable Growth Rate17.1344.53
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.